Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03253744 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

Start date: August 23, 2017
Phase: Phase 1
Study type: Interventional

Background: Prostate cancer is the second leading cause of cancer death in U.S. men. Radiation is an effective treatment for most patients with localized prostate cancer, but sometimes the tumor returns. Researchers want to see if a highly focused type of radiation can help. It is given in only 5 treatments. It is called stereotactic body radiation therapy (SBRT). Objective: To study the maximum tolerated dose and side effects of stereotactic body radiation therapy in people with a local recurrence of prostate cancer after radiation. Eligibility: Men at least 18 years old who have recurrent prostate cancer after radiation therapy and no evidence of distant metastatic disease Design: Participants will be screened with blood tests, physical exam, and medical history. They may also have: Magnetic resonance imaging (MRI) scan of the prostate.. PET/CT scan. Participants will get an injection of 18F-DCFPyL for the PET scan. They will lie very still on their back on the scanner table. Small samples of prostate tumor tissue will be taken by a needle through the skin or rectum to see if the cancer is in the prostate. Small metal seeds will be placed into the prostate at the same time to help guide the radiation. About 2 weeks later, participants will have a radiation treatment planning CT scan. Participants will answer questions about their urine function, bowel function, erectile function, and mood. Participants will receive SBRT. They will have 5 radiation treatments over 2 weeks. Participants will have follow-up visits. They will have a physical exam, blood tests, and questionnaires. Six months after ending SBRT, the 18F-DCFPyL PET/CT will be repeated....

NCT ID: NCT03252821 Not yet recruiting - Prostate Cancer Clinical Trials

Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy

Start date: August 15, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to assess the impact of a high-intensity aerobic training and resistance training on fatigue in prostate, head and neck and rectum cancer patients undergoing radiotherapy. A three-arm randomized controlled trial will be conducted. Patients will be randomised into either a high-intensity aerobic training group or a resistance training group or a control group. Participants in the training groups will exercised for five to eight weeks. Exercise sessions will be take place 3 days per week under the supervision of an experienced therapist. Subjects will be assessed at baseline and post-intervention. The primary outcome will be fatigue measured using the FACIT-fatigue questionnaire. The secondary outcomes will be: functional capacity, quality of life, executive functions, sleep disturbances, somnolence syndrome, insomnia, depression symptoms.

NCT ID: NCT03246347 Not yet recruiting - Prostate Cancer Clinical Trials

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.

NCT ID: NCT03232541 Not yet recruiting - Breast Cancer Clinical Trials

The Effects of Acupuncture and the Therapist´s Communication on Chemo-therapy Induced Nausea and Vomiting

Start date: July 28, 2017
Phase: N/A
Study type: Interventional

Background: Nausea and vomiting (emesis) is a common known problem for patients with cancer who are undergoing chemotherapy. Emesis affects both the patient´s quality of life and induces high costs within the health-care system. Acupuncture is an upcoming treatment for emesis, despite lacking evidence for effects beside non-specific effects since few credibly sham-controlled studies previously have been conducted. The therapist's care and communication during the needling sessions may induce non-specific effects, potentially driven by the patient's expectations. It is not known if the type of communication, in terms of how positive the therapist communicates regarding expected effects, affects the effect of acupuncture for emesis. Aims: The aim of this study is to investigate if chemotherapy-induced nausea, vomiting, and quality of life differ between patients who receive a) standard care including antiemetics, b) standard care plus sham acupuncture or c) standard treatment plus genuine acupuncture. The aim is also to investigate if chemotherapy-induced nausea, vomiting, and quality of life differ between patients who receive the above mentioned standard care, sham acupuncture, or genuine acupuncture by a therapist who emphasizes the positive expected outcomes of the treatment, compared to a therapist who communicates neutral regarding the outcomes. Procedure: The eligible patients will be randomized to A) standard care, including antiemetics or to B) standard treatment plus sham acupuncture or C) standard treatment plus genuine acupuncture. Within the three groups, the patients are randomized to receive either neutral or positive communication with the therapist during the treatment. Outcome measures: Nausea and vomiting are documented in questionnaires and in a diary, measured with Visual Analogue Scales. Well-being, activity level and quality of life are measured with questionnaires.

NCT ID: NCT03228108 Not yet recruiting - Prostate Cancer Clinical Trials

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

pro-SWAP
Start date: October 2017
Phase: Phase 4
Study type: Interventional

This study aims to assess the effectiveness and cost-effectiveness of rectal swab culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral ciprofloxacin (control group), while the other half will receive rectal culture-guided oral antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis, comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative oral antibiotic based on the culture results will be prescribed (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin). The investigators hypothesise that the targeted prophylaxis group (intervention group) will have a lower rate of post-biopsy infectious complications compared to the control group.

NCT ID: NCT03225222 Not yet recruiting - Prostate Cancer Clinical Trials

MRI in PROstate Cancer Diagnosis With Prior Risk Assessment

MR-PROPER
Start date: October 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

To evaluate the diagnostic performance and cost-effectiveness of the MRI-driven diagnostic pathway of prostate cancer, with upfront individual multivariate risk stratification.

NCT ID: NCT03213951 Not yet recruiting - Prostate Cancer Clinical Trials

Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection

Start date: July 2017
Phase: N/A
Study type: Observational

68Ga-PSMA is a radiopharmaceutical used with PET imaging for the detection of prostate cancer under a compassionate IND in patients who have presented with biochemical failure. In this study, the use of 68Ga-PSMA-11 will be extended to newly diagnosed patients with high risk prostate cancer. Patients enrolled to this study will undergo a 68Ga-PSMA-11 PET/CT or PET/MRI scan for research purposes (in addition to the routine CT or MRI that is routinely done for staging), and a second 68Ga-PSMA-11 administration just prior to surgery for experimental ex-vivo beta probe testing of resected tissue. Immediately following resection of the prostate, the intact tissue will be scanned using a PET camera designed for animal research in order to record the 68Ga-PSMA-11 distribution in the isolated tissue at higher resolution than can be attained using whole-body PET imaging. The experimental beta probe will then be use to measure 68Ga-PSMA-11 counts of the resected tissue.

NCT ID: NCT03207113 Not yet recruiting - Prostate Cancer Clinical Trials

Adoption, Acceptability and Effectiveness of a Mobile Health Application for Personalised Prostate Cancer Survivorship Care.

Start date: July 2017
Phase: N/A
Study type: Interventional

The Ned case study is a 12-month mixed methods embedded single-case study with a nested within-group pre-post comparison of health outcomes. 400 patients, 200 caregivers, and 10 clinicians will be given access to Ned. Participants will be asked to complete study assessments at baseline, 2 months, 6 months and 12 months. 30 semi-structured qualitative interviews with patients (n=20) and their caregivers (n=10) post-study will also be conducted to gain insight into their experience with the application.

NCT ID: NCT03203460 Not yet recruiting - Prostate Cancer Clinical Trials

Exercise During Active Surveillance for Prostate Cancer

ERASE
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The primary aim of this study is to examine the effects of exercise on anti-cancer immune activity related to tumour progression in prostate cancer patients undergoing active surveillance.

NCT ID: NCT03199586 Not yet recruiting - Breast Cancer Clinical Trials

Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)

Start date: September 1, 2017
Phase: Phase 1
Study type: Interventional

First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.